drugset / Trial / NCT05092880

Radioembolization in Elderly/ Fragile Patients With mCRC

NCT05092880 ↗

Phase 2 Terminated 18 enrolled UMC Utrecht Dutch Colorectal Cancer Group · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Radioembolization (RE) is a minimally invasive treatment with administration of radioactive microspheres into the hepatic artery via a microcatheter. Since tumors are preferentially supplied by the hepatic artery, most microspheres get trapped in the tumor. RE has been shown a feasible and safe procedure for the treatment of unresectable CRC liver metastases. These data compare favourably with the toxicity data of capecitabine plus bevacizumab, but this should be validated in a prospective study. The proposed study investigates the efficacy of RE as an alternative, better tolerated and more cost-effective treatment option in elderly or frail patients compared to chronic systemic treatment with comparable progression-free survival.

Timeline

Start
2022-06-01
Primary completion
2025-09-01
Completion
2025-09-01

Outcome

Outcome not reported

Stopped: “The medical deviced studied was taken off market”

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 Oral

Indications